As psychedelic treatments gain traction, analysts predict triple-digit upside for this small-cap biotech stock.
MindMed is a high-flying pre-revenue company that has more than doubled investor returns in the last 12 months.
Discover three under-the-radar biotech and medtech stocks that analysts believe could soar in 2024, each with unique growth drivers and significant upside potential.
For investors with a high level of risk tolerance, Mind Medicine could be an intriguing investment option.
EQNX::TICKER_START (NYSE:JNJ),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:ATAI),(NYSE:ABBV) EQNX::TICKER_END
Mind Medicine is a pre-revenue biopharma company that has more than doubled investor returns in 2024. Is MNMD stock a good buy today?
/CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing traditional and innovative...
About 43.8 million adults in the U.S. experience a mental health issue in a given year, according to the National Institute of Mental Health (NAMI). Nearly 16 million of those adults live with major depression....
At the moment, about 14 million people live with PTSD just in the U.S. Unfortunately, despite extensive clinical research, PTSD is still a significant unmet medical need. However, that may soon change...
EQNX::TICKER_START (NYSE:CYBN),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:SEEL),(NASDAQ:ATAI) EQNX::TICKER_END